Dihexa

People who look up Dihexa want a better memory, and often they want reassurance about the future too. The searches run from Dihexa benefits and Dihexa dosage to is Dihexa safe and Dihexa vs Semax. For a lot of women in their forties and fifties the trigger is personal. It's the name that won't come, the reason you walked into the kitchen, or a parent's diagnosis that makes every lost word feel like a warning.

Dihexa's reputation was built for exactly that worry. Vendor pages describe it as a compound that grows new connections between brain cells, and many repeat a line that it's "seven orders of magnitude" more potent than BDNF, the brain's own growth protein. The Alzheimer's Drug Discovery Foundation, an independent research charity, went looking for that comparison and reported that it isn't in the published research at all. It came from a press release.

It's easy to see why the story spread. A compound invented at a university, with a clear mechanism, a striking number attached and a pill form, is exactly what a worried reader hopes to find at midnight. The details underneath it are the part most listings leave out, and they're the part this page is for.

People also buy it for everyday focus. That's where the evidence is thinnest, because in the rat work Dihexa helped animals whose memory had been impaired by a drug or by age, and it didn't improve memory in rats that were normal to begin with.

Dihexa started as angiotensin IV, a small piece of the hormone system that controls blood pressure, which researchers noticed had an effect on memory in animals. They trimmed it down and added chemical groups to both ends so it would survive digestion and cross into the brain. Think of it as taking one useful sentence out of a long letter and laminating it.

The proposed mechanism is that Dihexa boosts HGF, short for hepatocyte growth factor, and its receptor, c-Met. That pair helps cells grow and connect, and in the brain that's meant to mean new connections between nerve cells. Rat studies reported more of the small branches nerve cells use to connect, and better results in a water maze memory test.

In April 2025 the journal that published the two papers establishing that mechanism retracted both, after a Washington State University investigation found falsified or fabricated figures. A third paper, the source of most of the efficacy numbers, has carried a formal notice of concern from the journal since 2021, which is a flag, not a withdrawal. A retraction doesn't prove Dihexa does nothing. It means the explanation everyone repeats is no longer supported, and nobody has redone that work. We covered it in the two Dihexa papers that were retracted.

Vendors sell Dihexa as capsules, as freeze-dried powder to mix and inject under the skin, and as nasal sprays. The capsule form exists because Dihexa worked when given by mouth in rats, which is unusual for a peptide-based compound.

There's no sourced human amount. The rat studies dosed it by body weight, and no study has worked out what that means for a person, so we don't print a conversion. Dihexa doesn't dissolve well in water, and the rat studies mixed it into a strong solvent called DMSO, so anyone mixing powder is likely to meet the same problem the researchers did. A listing that doesn't say how its version is meant to dissolve is worth a question to the vendor before you buy.

The research charity's review states that no studies in people or animals have looked at Dihexa's long-term safety. Two questions sit at the center of that gap.

The first is how long it stays in the body. In rats the half-life, the time it takes for half a dose to clear, was about 9 to 13 days depending on how it was given. The human figure has never been measured. A compound taken daily that takes over a week to clear builds up, and nobody knows where that level settles in a person.

The second is the pathway it's meant to switch on. c-Met is linked to cancer growth when it's overactive, and most cancer drugs aimed at that pathway are designed to block it. Dihexa is meant to do the opposite, and it hasn't been tested for any effect on tumors. The company that developed a related compound excluded anyone with a recent cancer diagnosis from its trials. That's a theoretical concern rather than a demonstrated one, and it's the question people with a personal or family history of cancer ask about first.

There's also no information on how Dihexa interacts with other medicines. Because its starting point is a piece of the blood-pressure hormone system, people on blood-pressure medication are among those who ask, and we found no study that tested the combination. Pregnancy and breastfeeding are unstudied too.

Beyond that, the everyday risk is the vial itself. Ask for an independent certificate of analysis that confirms identity and purity for the batch you're buying.

The one place this pathway reached people was fosgonimeton, a related compound from the same Washington State research, developed by Athira Pharma. Product pages sometimes call it "Dihexa in trials," and that's more than anyone can support. It's a different molecule from the same family.

Fosgonimeton passed an early safety trial, which measured brain-wave signals rather than memory. Then it went into a larger trial in people with mild to moderate Alzheimer's disease, and in September 2024 the company reported that it missed its main goal. Development stopped. That's the most useful fact anyone can give you about this pathway, because it was tested properly in people, and it didn't produce a benefit.

Dihexa isn't approved as a medicine anywhere, and the FDA hasn't approved it for anything. In the US it's sold as a research compound, labeled for research use, and buying it for that purpose is legal. Dihexa acetate is on the slate for the FDA's pharmacy compounding advisory committee, due to meet before the end of February 2027. Our story on the FDA's next compounding slate explains what that hearing can and can't decide.

We haven't written a Dihexa comparison yet. The compound people weigh it against most is Semax, the Russian focus peptide with an approved nasal drop and some human research behind it. People also ask about Pinealon, a three-amino-acid peptide studied for the aging brain, and our guide to what nootropics are puts all of them in context.

If memory is the worry that brought you here, the compounds with more behind them are worth a look first. Semax has an approved product and human research in Russia, and Pinealon has a longer line of cell and animal work, without a retraction hanging over it.

As for buying it, no vendor we track lists it right now. If you find it, compare the real cost per milligram, and buy from a seller that publishes independent identity and purity testing for the lot you're getting.

It's sold for research, and it has never been tested in a person.